1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Iressa - gefitinib -Oncology drug report -  2002-2015 analysis; 2016-2021 expectations

Iressa - gefitinib -Oncology drug report - 2002-2015 analysis; 2016-2021 expectations

  • December 2016
  • 42 pages
  • ID: 4547464
  • Format: PDF
  • By Cancer Research Analytics


Table of Contents

Search Inside

“Iressa: on a downward spiral” is a comprehensive drug report about the first EGFR tyrosine kinase inhibitor drug in the NSCLC market.

Iressa is the first drug in the EGFR-TKI market to be approved for non-small cell lung can-cer. It belongs to AstraZeneca’s portfolio and falls in targeted therapy, under the tyrosine kinase inhibitor class of drugs. It is indicated for the treatment locally advanced or meta-static NSCLC.

The report gives basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about Iressa, information on competitor drugs, number of clinical trials (by year and by phase), and so on.
The report gives an analysis of the historical annual sales (from 2006-2015), historical quarterly sales (Q1-2013 to Q3-2016) and sales expectations (from 2016-2021). The analy-sis broadly indicates that the drug had a strong start but is losing out to competition now and its patent is pending expiry in different geographies starting 2017.
Details of the sales analysis section
Historical annual sales analysis: Historical annual sales have been analysed with the help of graphical representation of sales over 2006-2015. The report has all the data in tabular format as well. We have highlighted key reasons for the sales trend in all the geographies listed.
Historical quarterly sales analysis: Additionally, we have shown sales analysis on quarterly basis for the past 15 quarters from Q1-2013 to Q3-2016. The quarterly data is also in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for Iressa sales over 2016-2021. We have highlighted the key reasons for our expectations. All the historical as well as ex-pected sales analysis is based on:
1. Total global sales
2. US sales
3. International sales
(a) Western Europe
(b) Established RoW
(c) Emerging Markets

Other important details
Key event tracker: The report highlights key events that have taken place for Iressa from 2002 to 2016. It gives additional information about the key events that have driven sales for the drug over this period.
Clinical trial numbers: The report provides numbers of clinical trials which have started for Iressa in 2014, 2015 and 2016 and for different phases: phase-II, phase-II/III and phase-III.
Competitive drugs: Additionally, all the drugs which compete/can compete with Iressa in EGFR-TKI NSCLC are listed with their details including brand name, API, company, class of drug, therapy class and treatment preference.
Clinical studies: Efficacy results of Iressa and its competing drugs have been provided.
DMF filing: We have given list of DMFs filed of Iressa
News: We have listed news related to Iressa that would impact the drug’s performance.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on